Sofinnova Partners leads €13 million seed-extension round in Ingenix

UnitedHealth Group

UnitedHealth Group

UNH

0.00
  • Ingenix, an AI-and-biology drug development company, raised a EUR 13 million seed-extension round led by Sofinnova Partners.
  • Funding targets scale-up of its Biological Reasoning Engine, which fuses multiple biological data modalities to support drug discovery decisions.
  • Ingenix also plans to expand work with pharma and biotech partners through a new Qualified Access Program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.